Last $5.30 USD
Change Today -0.08 / -1.49%
Volume 1.4M
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

orexigen therapeutics inc (OREX) Snapshot

Open
$5.35
Previous Close
$5.38
Day High
$5.49
Day Low
$5.23
52 Week High
07/31/13 - $7.84
52 Week Low
11/5/13 - $4.60
Market Cap
591.2M
Average Volume 10 Days
2.5M
EPS TTM
$-0.80
Shares Outstanding
111.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OREXIGEN THERAPEUTICS INC (OREX)

orexigen therapeutics inc (OREX) Related Businessweek News

No Related Businessweek News Found

orexigen therapeutics inc (OREX) Details

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.

50 Employees
Last Reported Date: 03/13/14
Founded in 2002

orexigen therapeutics inc (OREX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.2M
Acting Chief Financial Officer, Principal Acc...
Total Annual Compensation: $592.0K
Head of Global Contrave Program and Senior Vi...
Total Annual Compensation: $610.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $592.0K
Chief Commercial Officer
Total Annual Compensation: $470.9K
Compensation as of Fiscal Year 2012.

orexigen therapeutics inc (OREX) Key Developments

Orexigen Therapeutics, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

Orexigen Therapeutics, Inc. announced unaudited earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, the company reported a net loss of $21.485 million, or $0.21 per basic and diluted share compared to $32.455 million or $0.41 per basic and diluted share a year ago. The company reported total revenues of $0.857 million and loss from operations of $20.956 million against total revenues of $0.857 million and loss from operations of $32.477 million a year ago. For the year, the company reported total revenues of $3.428 million, loss from operations of $77.198 million and net loss of $77.671 million or $0.80 per basic and diluted share against total revenues of $3.428 million, loss from operations of $90.239 million and net loss of $90.094 million or $1.27 per basic and diluted share for the same period a year ago.

Orexigen Therapeutics, Inc. to Report Q4, 2013 Results on Mar 12, 2014

Orexigen Therapeutics, Inc. announced that they will report Q4, 2013 results at 5:00 PM, Eastern Standard Time on Mar 12, 2014

Orexigen Therapeutics, Inc., Q4 2013 Earnings Call, Mar 12, 2014

Orexigen Therapeutics, Inc., Q4 2013 Earnings Call, Mar 12, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OREX:US $5.30 USD -0.08

OREX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OREX.
View Industry Companies
 

Industry Analysis

OREX

Industry Average

Valuation OREX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 159.7x
Price/Book 13.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 100.1x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit www.orexigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.